Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
DeepMind, a London-based AI company acquired by Google back in 2014, is sharing predictions made by its advanced AlphaFold system that could help researchers learn more about the new coronavirus.
As more cases of the new coronavirus, COVID-19, are being confirmed globally and in the U.S., researchers have revealed the incubation period for the virus is estimated to be 5.1 days.
Amazon, the e-commerce giant that continues to increasingly dip its toe into the healthcare space, is reportedly working on a vaccine that could cure the common cold, according to CNBC.
The newly incorporated American Board of Artificial Intelligence in Medicine (ABAIM) is soon to begin credentialing healthcare workers in AI, machine learning and deep learning.
Owkin, a New York City-based AI startup, announced it is now working with the University of Pittsburgh to design and validate advanced machine learning models. Once finalized, the new models are expected to have a significant impact in areas such as clinical research and the development of pharmaceuticals.
Countless studies have explored AI’s impact on healthcare providers and the patients they serve—but what about the financial side of things? Looking purely at the bottom line, is AI a wise investment?
